Holen Sie sich die Stockscreener-App
59.08
0.16%
0.13
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$58.95
Offen:
$59.67
24-Stunden-Volumen:
4.24M
Relative Volume:
0.32
Marktkapitalisierung:
$120.27B
Einnahmen:
$48.19B
Nettoeinkommen (Verlust:
$7.06B
KGV:
17.08
EPS:
3.4587
Netto-Cashflow:
$12.85B
1W Leistung:
-2.07%
1M Leistung:
-2.79%
6M Leistung:
+27.80%
1J Leistung:
-2.05%
1-Tages-Spanne:
$58.75
$60.06
1-Wochen-Bereich:
$58.32
$60.95
52-Wochen-Spanne:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.06 | 120.05B | 48.19B | 7.06B | 12.85B | 3.4587 |
|
LLY
Lilly Eli Co
|
990.67 | 872.68B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.20 | 583.29B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
223.15 | 398.49B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
190.74 | 298.53B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
154.14 | 294.33B | 54.72B | 14.02B | 15.32B | 7.1855 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol-Myers Squibb Co. (NYSE:BMY): A High-Yield Dividend Stock for Income Investors - ChartMill
Bristol Myers Squibb Company $BMY Shares Sold by Employees Retirement System of Texas - MarketBeat
Colgate-Palmolive Elects Christopher Boerner, Ph.D. to Board of Directors - citybiz
Colgate-Palmolive raises dividend, adds Bristol Myers CEO to board By Investing.com - Investing.com India
Is Bristol Myers' Deep Pipeline the Key to Future Growth? - The Globe and Mail
Piper Sandler Sees Path to Growth for Bristol-Myers Squibb Company (BMY) After Eliquis Patent Expiry - Insider Monkey
UBS Boosts Bristol-Myers Squibb (BMY) Price Target as Milvexian Data Looms - Insider Monkey
BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture - Benzinga
LGT Fund Management Co Ltd. Has $372,000 Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Readies New Growth Drivers In Immunology And Cancer - simplywall.st
Bristol Myers Squibb (NYSE:BMY) Boosts Research Strengthening S&P 500 Index Momentum - Kalkine Media
Bristol Myers Squibb reports positive phase 3 trial results - Investing.com
Bristol's cancer treatment meets main goal in late-stage trial - AOL.com
Bristol's drug enhances survival rates in late-stage blood cancer trial - Reuters
New Bristol Myers pill delays myeloma progression in key late-stage trial - Stock Titan
Blair William & Co. IL Reduces Bristol Myers Squibb Stake - National Today
Oral Mucositis Market Set to Boom Through 2033 | Bristol-Myers Squibb • Pfizer Inc. • Novartis AG - openPR.com
Pitcairn Co. Sells 20,260 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
B. Metzler seel. Sohn & Co. AG Has $5.05 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers (BMY) Gains FDA Approval for Sotyktu in Psoriatic Arthritis Treatment - GuruFocus
Munich Reinsurance Co Stock Corp in Munich Takes $2.78 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Has $43.66 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb's Sotyktu Approved for Psoriatic Arthritis Treatment - Intellectia AI
Bristol Myers Wins FDA Approval for Sotyktu for Psoriatic Arthritis - Benzinga
Bristol Myers wins FDA nod to expand Sotyktu label (BMY:NYSE) - Seeking Alpha
Painful psoriatic arthritis gets new oral option with FDA Sotyktu approval - Stock Titan
UBS raises Bristol-Myers Squibb stock price target on pipeline outlook - Investing.com
Why Bristol-Myers Squibb Remains a Top Healthcare Dividend Stock Pick - Tokenist
IFG Advisory LLC Acquires New Position in Bristol Myers Squibb Company - National Today
Edgar Lomax Co. VA Reduces Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb's Cancer Drug Meets Key Trial Goals - Intellectia AI
Is It Too Late To Consider Bristol Myers Squibb (BMY) After Recent Share Price Strength? - simplywall.st
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? - TradingView
Assessing Bristol Myers Squibb (BMY) Valuation After Recent Share Price Momentum And 2024 Results - simplywall.st
Bristol Myers Squibb Awaits FDA Verdict On Sotyktu In Psoriatic Arthritis - RTTNews
Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks - Finviz
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
How New Oncology Wins and a Fresh Dividend At Bristol Myers Squibb (BMY) Have Changed Its Investment Story - simplywall.st
Wealthedge Investment Advisors Boosts Bristol Myers Squibb Holdings - National Today
Bristol Myers Squibb declares $0.63 quarterly dividend - Investing.com
APG Asset Management Trims Bristol Myers Squibb Stake - National Today
Elo Mutual Pension Insurance Co Increases Bristol Myers Squibb Position - National Today
Bristol-Myers Squibb (BMY) Maintains Quarterly Dividend of $0.63/Share - GuruFocus
Bristol Myers Squibb at TD Cowen Conference: Strategic Growth Amid Challenges - Investing.com
BMY Gains 11.4% in a Month: Should You Buy, Sell or Hold the Stock? - TradingView
Evinova and Bristol Myers Squibb Collaborate to Advance AI-Driven Clinical Development - The Healthcare Technology Report.
Elo Mutual Pension Insurance Co Has $13.63 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
What Bristol-Myers Squibb (BMY)'s Triple-Negative Breast Cancer Phase III Survival Win Means For Shareholders - Yahoo Finance
Bristol-Myers Squibb Cancer Advances Test Valuation Gap For Investors - simplywall.st
Is Bristol Myers Squibb (BMY) Pricing Look Attractive After Recent Share Price Climb - Yahoo Finance
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):